Beat the Beast: Remdesivir - The New Corona Killer?


An interesting article on COVID-19 treatments by Nell Sloane.


Why Investors Are Hanging So Much Hope on Remdesivir: More than 20 publicly traded companies are working on evaluating drugs that could potentially treat the novel coronavirus disease. Several of those candidates come from well-known names like Bayer and Eli Lilly, but it's Gilead's remdesivir drug that investors are following most closely. Health experts say it's the drug furthest along in clinical studies and results from one of the company's late-stage trials is expected as soon as today. Keep in mind, two separate leaked reports about remdesivir trials over the last couple of weeks seem to have had broad market impacts. The first, showing remdesivir was highly effective in treating Covid-19 patients, came out on April 17, a day the Dow rallied over +700 points. The other, posted on April 23, said the drug didn't show any clinical benefit at all, which traders blamed for quashing a rally and a -5% decline in Gilead's stock. Gilead will also be releasing results from another of its late-stage trials in May which could coincide with results from the U.S National Institute of Allergy and Infectious Disease's (NIAID) own late-stage study of remdesivir. read more here

Thanks

Nell



1 view0 comments

Recent Posts

See All

After the Close March First

Interest Rate Margin changes to go in effect at The CME. See them here https://www.cmegroup.com/notices/clearing/2021/02/Chadv21-074.html

Some Really Good Numbers This Morning

Weekly Jobless claims drop more than 100,000 although that may be deceiving due to weather conditions across the country last week. Durable goods up over 3% when only 1% or so was expected. Jeff Cox o

Jump in Weekly Claims

Weekly Jobless Claims are much higher than expected. Santelli spells it out very well as always. https://www.cnbc.com/2021/02/18/us-jobless-claims-.html?__source=newsletter%7Cbreakingnews

Fractal Finance

872-225-2110 ext. 2

FAX: 872-225-2110

  • facebook
  • twitter
  • linkedin

©2020 BY QUANT TRADE, LLC. QUANT TRADE, LLC IS NOT RESPONSIBLE FOR CLIENT OR SUBSCRIBER LOSSES. TRADING FUTURES, STOCKS, FOREX AND OPTIONS INVOLVES THE RISK OF LOSS. YOU SHOULD CONSIDER CAREFULLY WHETHER FUTURES, STOCKS, FOREX AND OPTIONS ARE APPROPRIATE TO YOUR FINANCIAL SITUATION. YOU MUST REVIEW THE CUSTOMER ACCOUNT AGREEMENT AND RISK DISCLOSURE PRIOR TO ESTABLISHING AN ACCOUNT. ONLY RISK CAPITAL SHOULD BE USED WHEN TRADING FUTURES, STOCKS, FOREX AND OPTIONS. INVESTORS CAN LOSE MORE THAN THEIR INITIAL INVESTMENT. PAST RESULTS ARE NOT NECESSARILY INDICATIVE OF FUTURE RESULTS. THE RISK OF LOSS IN TRADING FUTURES OR OPTIONS CAN BE SUBSTANTIAL, CAREFULLY CONSIDER THE INHERENT RISKS OF SUCH AN INVESTMENT IN LIGHT OF YOUR FINANCIAL CONDITION. INFORMATION CONTAINED, VIEWED, SENT OR ATTACHED IS CONSIDERED A SOLICITATION.